a

Asterias Biotherapeutics stem cell study for SCI shows promising results: 4 notes

Written by  Megan Wood | Wednesday, 14 June 2017 20:28
Social sharing

Asterias Biotherapeutics' SCiStar Phase 1/2a clinical study yielded positive outcomes for patients with complete cervical spinal cord injury.

Here are four notes:

 

1. The nine-month study tested the efficacy and safety study of AST-OPC1, a human stem cell-based treatment for SCI patients.

 

2. Researchers saw three out of six patients, treated with 10 million cells, achieved two motor levels of improvement over baseline on at least one side following treatment.

 

3. All six patients experienced at least one motor level of improvement on at least one side.

 

4. Researchers presented the data at a pre-meeting workshop at the International Society for Stem Cell Research 2017 Annual Meeting in Boston from June 14 to June 17.

 

More articles on spine:
How to save up to $422 on adult spinal deformity surgery: 5 key points
Drs. Ashish Patel, Elian Shepherd perform simultaneous surgery to lower complications: 5 insights
Orthopedic spine surgeon Dr. Max Burrs dies at 76

© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months